A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

Published:2017-12 Issue: Volume:114 Page:96-102
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tu Hai-Yan,Ke E-E,Yang Jin-Ji,Sun Yue-Li,Yan Hong-Hong,Zheng Ming-Ying,Bai Xiao-Yan,Wang Zhen,Su Jian,Chen Zhi-Hong,Zhang Xu-Chao,Dong Zhong-Yi,Wu Si-Pei,Jiang Ben-Yuan,Chen Hua-Jun,Wang Bin-Chao,Xu Chong-Rui,Zhou Qing,Mei Ping,Luo Dong-Lan,Zhong Wen-zhao,Yang Xue-Ning,Wu Yi-Long

Funder

Hangzhou Science and Technology Bureau

National Health and Family Planning Commission of the People's Republic of China

National Key Research and Development Program of China

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N. Engl. J. Med.,2009

2. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung;Han;J. Clin. Oncol.,2012

3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010